Parent and patient testimony about the life-altering changes they experienced with Biomarin Pharmaceutical Inc.'s Kyndrisa wasn't enough to wholeheartedly convince an FDA advisory committee of the efficacy of the exon 51-skipping drug for Duchenne muscular dystrophy (DMD).